ABPRO Conducts Primate Trials for COVID-19 Treatment... 'Complete Virus Eradication' Published in Nature Journal

[Asia Economy Reporter Hyunseok Yoo] The results of primate experiments for ‘ABP-300,’ a candidate therapeutic agent for the novel coronavirus infection (COVID-19) developed by ABPROBIO’s U.S. subsidiary ‘ABPRO Corporation,’ have been published in the journal Nature.

ABPROBIO announced on the 18th that Mabwell Bioscience, a Chinese company co-developing the COVID-19 therapeutic candidate ‘ABP-300,’ published the results of primate experiments on ABP-300 in Nature.

Through primate experiments, ABPROBIO successfully demonstrated the preventive and therapeutic efficacy of ‘ABP-300’ against COVID-19. To confirm the preventive effect, three monkeys were each administered 20mg/kg of ABP-300 and then inoculated with the COVID-19 virus. As a result, no COVID-19 virus was detected in the treated group.

In the experiment for therapeutic efficacy, monkeys inoculated with the COVID-19 virus were administered 40mg/kg of ABP-300 one week after virus inoculation. Compared to the control group, COVID-19 was significantly reduced. After three days of ABP-300 administration, the virus was completely eliminated.

An ABPROBIO official stated, “ABP-300 has already completed global Phase 1 clinical trials, and with this publication, its excellent preventive and therapeutic effects have been externally validated.” He added, “Global Phase 2 clinical trials are scheduled to begin in November. Clinical trials in China have already been confirmed, and trials will also be conducted in Japan, Brazil, and the Philippines.” He further noted, “Once the global Phase 2 trials are completed, Phase 3 clinical trials for ABP-300 will immediately commence in the United States in the first half of next year.”

ABP-300 is a COVID-19 neutralizing antibody therapeutic based on ‘monoclonal antibodies’ isolated to bind only to specific viral antigens. It is designed to respond to various variants. It applies ‘recombinant proteins’ of the ‘receptor-binding domain’ for the eight most frequently occurring COVID-19 variants, thereby possessing neutralizing ability against major variants.

In addition to its effectiveness against variant COVID-19 viruses, ABP-300 has shown a reduction effect on ‘antibody-dependent enhancement (ADE),’ making it competitive as a COVID-19 therapeutic. ADE is a phenomenon where viruses invading the body use antibodies that neutralize the virus to rapidly spread to host cells, worsening symptoms. This is the biggest challenge to overcome in developing COVID-19 antibody therapeutics. ABP-300 has succeeded in reducing ADE without loss of efficacy, thereby verifying excellent safety.

This content was produced with the assistance of AI translation services.